New prostate drug enters early safety testing
NCT ID NCT07404735
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called CKD-846 in 32 healthy men with benign prostate hypertrophy (enlarged prostate). The main goal is to see how the drug moves through the body and if it is safe. Participants must be men aged 19 to 55 with a healthy weight.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN PROSTATE HYPERTROPHY(BPH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One-shot hormone blocker may prevent repeat urinary blockages in men
- Steam power: can a quick vapor treatment ease prostate symptoms for years?
- New study pits two prostate surgeries Head-to-Head for better outcomes
- Natural supplement combo may match standard drug for prostate relief
- CoQ10 supplement tested for prostate relief
- Which prostate procedure spares your sex life? new study has answers